載入...

Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20(+) B Cell Malignancies

We previously reported a 24% 1-year relapse rate in 93 older or medically unfit patients with CD20(+) B cell malignancies after allogeneic hematopoietic cell transplantation (HCT) with low-intensity conditioning. The current prospective study tested the hypothesis that disease relapse could be reduc...

全面介紹

Na minha lista:
書目詳細資料
發表在:Biol Blood Marrow Transplant
Main Authors: Granot, Noa, Rezvani, Andrew R., Pender, Barbara S., Storer, Barry E., Sandmaier, Brenda M., Storb, Rainer, Maloney, David G.
格式: Artigo
語言:Inglês
出版: 2020
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7549403/
https://ncbi.nlm.nih.gov/pubmed/32693210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2020.07.014
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!